Spectral AI Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spectral AI excels in Q2, eyes FDA approval and revenue growth

Spectral AI's strong Q2 performance, progress in AI technology, and strategic initiatives position them well for future growth. While facing challenges in FDA approval and commercialization, the company's cash position and revenue guidance offer stability and potential. Opportunities for growth through government contracts and capital access further enhance their prospects.

Spectral AI Inc reports robust Q3 results, eyes AI expansion

Spectral AI Inc (MDAI) demonstrated strong financial performance in Q3 2024, with revenue growth, improved margins, and a focus on key study milestones.
The company's strategic partnerships, clear priorities, and upcoming data release position it well for future growth and innovation in the medical AI space.
While facing challenges in regulatory compliance and market expansion, Spectral AI Inc has opportunities to diversify its offerings, enter new markets, and solidify its position as a leader in AI-based medical treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectral AI, Inc. is a predictive artificial intelligence company. It focuses on medical diagnostics for faster and more accurate treatment decisions in wound care for burn, DFU, and future clinical applications. Its DeepView platform is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company was founded on November 17, 2020 and is headquartered in Dallas, TX.

Spectral AI (NASDAQ: MDAI ) stock is on the rise Tuesday after the artificial intelligence ( AI ) company announced a $500,000 government contract for its wound imaging technology. According to a press release from Spectral AI, it's teaming up with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA).

Why Is Spectral AI (MDAI) Stock Up 15% Today?

Leading medical diagnostics artificial intelligence company Spectral AI Inc. (NASDAQ: MDAI) announced on Monday that it had secured a new contract with the Defense Health Agency and the U.S.

How Much Could New Army Contract Boost This AI Stock?

Spectral AI Inc (NASDAQ:MDAI) announced that it has secured a contract with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA) to support the development of the handheld version of its DeepView Wound Imaging System, DeepView SnapShot M, which is targeting battlefield use.  The company said the contract was valued at more than $500,000 and brings the total awarded to advancing the DeepView SnapShot M to more than $6 million.

Spectral AI wins US government contract to develop handheld DeepView wound imaging system

In the past six months, the Company has announced over $149 million of non-dilutive financing from the US Government for the DeepView™ Wound Imaging System In the past six months, the Company has announced over $149 million of non-dilutive financing from the US Government for the DeepView™ Wound Imaging System

Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System

Enthusiasm over the prospects for artificial intelligence (AI) continues to be a significant driver for many stocks, including several of the so-called Magnificent Seven.

This AI Stock Plunged 83% but Wall Street Expects a 133% Return in 2024

Spectral AI Inc (NASDAQ:MDAI) announced that it has created a wholly-owned subsidiary dedicated to advancing intellectual property (IP) related to the broader AI ecosystem, with a focus on healthcare. “After conducting a comprehensive review of our IP portfolio, we are confident that Spectral AI has effectively safeguarded its current and anticipated future product offerings through a combination of patents and trade secrets,” Spectral AI CEO Pete Carlson said in a statement.

Spectral AI to advance AI-driven healthcare solutions through new subsidiary

DALLAS, March 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare.

Spectral AI Announces Intellectual Property Subsidiary to Focus on the Broader AI Healthcare Ecosystem

Appointment Paves the Way for Company's Next Chapter in Commercialization Phase of AI-Powered DeepView Device for Predictive Wound Care

Spectral AI Appoints Peter M. Carlson as CEO

Spectral AI Inc (NASDAQ:MDAI) announced that its predictive software DeepView AI-Burn has received the final stage of the UK Conformity Assessed (UKCA) authorization for aiding in burn wound diagnosis in the United Kingdom. The medical devices firm said it expects to soon deploy six of its DeepView devices in the UK for customer evaluation which is expected to generate revenue starting in the second half of 2024.

Spectral AI sees revenue starting in 2024 from DeepView burn diagnosis system after securing UKCA Authorization

DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company ”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI®-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom.

Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024

T Stamp

All eyes are on NVIDIA Corp (NASDAQ:NVDA, ETR:NVD) this week ahead of its earnings report due Wednesday as the chipmaker targets another quarterly revenue record of $20 billion. The company, which makes semiconductor chips for AI applications, has seen its shares soar by about 230% in the last year, driven by investor enthusiasm for all things AI.

Forget Nvidia: AI stocks with significant growth potential to watch

Spectral AI Inc (NASDAQ:MDAI), the medical technology company, appointed founder and former boss Michael DiMaio as a non-executive director last week, replacing the position left by Michael Murphy. DiMaio served as the company's chief executive officer and chairman between 2011 and 2020, with all disputes surrounding his exit having been “amicably resolved”.

Spectral AI founder and ex-boss returns as director

The Company's two largest stockholders holding approximately 45% of the Company's outstanding shares have extended their lock-up agreements for an additional 180 days The Company's two largest stockholders holding approximately 45% of the Company's outstanding shares have extended their lock-up agreements for an additional 180 days

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

DALLAS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Spectral AI to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Spectral AI Inc (NASDAQ:MDAI) has told investors that interim results of ongoing clinical trials designed to validate its DeepView System will be “promising”. This includes tests of the medical imaging company's DeepView system in offering wound healing assessments in burn victims and those with diabetic foot ulcers.

Spectral AI closing in on commercial revenue from DeepView system

DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the publication of a Letter to Shareholders from the Company's CEO and Co-founder, Wensheng Fan, and Chairman of the Board, Richard Cotton.

Spectral AI Announces Publication of Letter to Shareholders

Spectral AI Inc (NASDAQ:MDAI) subsidiary Spectral MD announced that it has submitted an application in the United Kingdom for its predictive software DeepView AI-Burn to be registered as UK Conformity Assessed (UKCA) for burn use in the country. The company highlighted that the software DeepView AI-Burn integrates with its UKCA-granted application for its imaging device DeepViewSnapShot.

Spectral AI moves towards commercialization of burn care predictive software with UKCA mark application

DALLAS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (NASD: MDAI; MDAIW) (“Spectral AI” or the “Company ”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the submission of an application in the United Kingdom for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed (UKCA) for burn wound use in the UK.

Spectral Submits Application for UKCA Mark Classification

Spectral AI Inc (NASDAQ:MDAI) said it has started enrollment for a pivotal study of DeepView AI, utilizing its proprietary imaging technology for burn size and healing assessment. The study is a crucial step towards obtaining FDA marketing authorization for burn indication in 2025, the Dallas-based company said in a statement.

Spectral AI initiates pivotal study for DeepView AI in burn care

DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.

Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries

Spectral AI Inc (NASDAQ:MDAI) announced that it has appointed Peter Carlson as its chief financial officer. Carlson has previously served as CFO at MiMedx Group, chief operating officer at Brighthouse Financial, and chief accounting officer at MetLife.

Spectral AI taps experienced exec as new CFO

DALLAS, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced the hiring of Peter M. Carlson as Chief Financial Officer today.

Spectral AI Names Industry Veteran and Former Top MiMedx Financial Executive Peter M. Carlson as CFO

DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced that it will participate in the Benchmark 12th Annual Discovery One-on-One Conference being held on December 7, 2023 in New York City.

Spectral AI to Participate in Benchmark's 12th Annual Discovery One-on-One Conference

Spectral AI Inc (NASDAQ:MDAI) has announced the appointment of Erich Spangenberg, the company's largest shareholder, to its board of directors, who will serve as Executive Committee chairman as well as on the Nominating and Corporate Governance Committee.  The predictive AI company focused on medical diagnostics said Spangenberg has 40 years of experience as an entrepreneur, investor, investment banker, and attorney, as is the founder and managing director of Sauvegarder Investment Management, a multi-strategy investment firm dedicated to IP-related financings.

Spectral AI appoints IP veteran Erich Spangenberg as Executive Committee chairman

DALLAS, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced the appointment of Erich Spangenberg to the Board of Directors (“Board”). Mr. Spangenberg will serve as Chairman of the Company's Executive Committee as well as the Nominating and Corporate Governance Committee.

News for Spectral AI Inc Stock (MDAI)